ONCAlert | Upfront Therapy for mRCC

Genitourinary Cancers VIEW MORE >>

The FDA has granted a Priority Review to the New Drug Application for olaparib as treatment for patients with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations, who have progressed following prior treatment with a new hormonal agent, AstraZeneca reported in a press release.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.